Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Some diabetes meds might lower risk of dementia, Parkinson's
A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.
Type 2 drugs could lower dementia, Parkinson's disease risk
Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in particular.
Some Diabetes Drugs May Protect Against Dementia and Parkinson's
Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.
SGLT2 inhibitors reduce dementia, Parkinson’s disease risk: study
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds.
These Diabetes Drugs Could Help Lower Your Risk of Dementia, Parkinson’s
According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or SGLT2 inhibitors, stop the kidneys from reabsorbing too much blood glucose to improve blood sugar levels.
Some diabetes drugs tied to lower risk of dementia, Parkinson's disease
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in the September 18, 2024, online issue of Neurology.
Diabetes Medications May Lower Risk of Dementia and Parkinson's Disease
A recent study suggests that a class of diabetes medications could be linked to a reduced risk of developing dementia an..|News Track
SGLT2 inhibitors tied to lower risk of dementia, Parkinson's disease, suggests study
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in the September 18, 2024, online issue of Neurology®,
Medscape
9d
SGLT2 Inhibitor Reduces Risk for Neurodegenerative Diseases in T2D
"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...
Daily
11d
Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits
Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...
TCTMD
1d
Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF
When surveyed, many physicians said the belief that patients had adequate symptom control was why they didn’t add more meds.
Medscape
11d
Do SGLT2 Inhibitors Benefit Everyone With T2D and CKD?
New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback